



## Repair Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference

September 2, 2021

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Sep. 2, 2021-- Repair Therapeutics Inc. ("Repair" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 19<sup>th</sup> Annual Morgan Stanley Virtual Global Healthcare Conference on Thursday, September 9 at 2:45 p.m. Eastern Time.

A live webcast of the fireside chat can be accessed in the Investor section of the Company's website at <https://ir.reparerx.com/news-and-events/events>. A replay of the webcast will be archived on the Company's website for 30 days.

### About Repair Therapeutics, Inc.

Repair Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx<sup>®</sup> platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs. For more information, please visit [reparerx.com](http://reparerx.com).

SNIPRx<sup>®</sup> is a registered trademark of Repair Therapeutics Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210902005249/en/): <https://www.businesswire.com/news/home/20210902005249/en/>

### Repair Contact:

Steve Forte  
Chief Financial Officer  
Repair Therapeutics Inc.  
[info@reparerx.com](mailto:info@reparerx.com)

### Investors:

Kimberly Minarovich  
Argot Partners  
[repare@argotpartners.com](mailto:repare@argotpartners.com)

### Media:

David Rosen  
Argot Partners  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)  
212-600-1902

Source: Repair Therapeutics Inc.